{
  "compound": "Cannabidiol (Epidiolex)",
  "condition": "EPILEPSY",
  "effect_size": "Sustained large effect",
  "study_type": "OBSERVATIONAL",
  "source": "NORML:EPILEPSY_OBSERVATIONAL_001",
  "participants": "607 patients (Dravet + LGS combined)",
  "year": 2019,
  "notes": "Long-Term Safety of Epidiolex: Open-Label Extension Study",
  "confidence": "medium",
  "abstract": "Sustained efficacy over 3 years; No tolerance development; 50% maintained \u226550% reduction at 2 years"
}